New User:

Forgot your password?

Stock Market & Financial Investment News

News For SGYP;PRXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
10:25 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
November 16, 2015
16:53 EDTSGYPPaulson reduced stake in Valeant
Paulson & Co. gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Perrigo (PRGO), CIT Group (CIT), Precision Castparts (PCP), Cameron (CAM), and Altera (ALTR). INCREASED STAKES: Teva (TEVA), Post Holdings (POST), Starwood Hotels (HOT), LivaNova (LIVN), and Synergy Pharmaceuticals (SGYP). DECREASED STAKES: Valeant (VRX), Shire (SHPG), Whiting Petroleum (WLL), Computer Sciences (CSC), and Oasis Petroleum (OAS). LIQUIDATED STAKES: Houghton Mifflin Harcourt (HMHC), Broadcom (BRCM), and Sprint (S).
06:01 EDTSGYPSynergy Pharmaceuticals appoints Gary Sender as CFO
Subscribe for More Information
November 12, 2015
09:02 EDTPRXLPAREXEL, KPU announce joint program for clinical research
PAREXEL International Corporation and Kyoto Pharmaceutical University, or KPU, a private pharmacy and science university, today announced the new Joint Program for Clinical Research and Clinical Trial Management. The academic program offers undergraduate students an accredited, seven-week course designed to prepare them for careers in the biopharmaceutical industry. The collaboration is intended to meet the needs of a growing number of Japanese biopharmaceutical companies conducting clinical research inside and outside of Japan as part of global drug development initiatives. The course combines PAREXEL's extensive regulatory and clinical research expertise with Kyoto Pharmaceutical University's extensive experience developing highly-specialized research abilities in their "pharmacist-scientists" students. All classes will be conducted in English by non-Japanese lecturers from the PAREXEL Academy and are consistent with global clinical trial standards and practices. The first session begins in KPU's fiscal year 2016 and will be offered annually.
08:02 EDTSGYPSynergy Pharmaceuticals still a saleable asset, says Canaccord
Canaccord still views Synergy Pharmaceuticals (SGYP) as a saleable asset, with Valeant (VRX) or Shire (SHPG) seen as the most obvious buyers. The firm also sees the cost of the launch of plecanatide as lower than expected and sees no need for the company to raise capital until at least the end of 2016. Canaccord reiterated its Buy rating and $19 price target on Synergy Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use